https://orcid.org/0000-0002-8370-9562
References
- Wang R, Li Z, Liu S, et al. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the global burden of disease study 2019. BMJ Open. 2023 Mar;13(3):e065186. doi: 10.1136/bmjopen-2022-065186
- Argollo M, Kotze PG, Kakkadasam P, et al. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol. 2020;17(11):702–710. doi: 10.1038/s41575-020-0352-2
- UChicagoMedicine. Biologics and inflammatory bowel disease (IBD). [cited 2024 Feb 21]. Available from: https://www.uchicagomedicine.org/conditions-services/inflammatory-bowel-disease/treatment/biologics-and-inflammatory-bowel-disease-ibd-crohns-colitis
- Cury DB, de Souza Cury M, Elias GVH, et al. Infliximab to treat severe ulcerative colitis. World J Gastroenterol. 2009 Apr;15(14):1771–1773. doi: 10.3748/wjg.15.1771
- Zhao M, Sall Jensen M, Knudsen T, et al. Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases – a Danish nationwide cohort study. Aliment Pharmacol Ther. 2022;55(5):541–557. doi: 10.1111/apt.16723
- Ashraf H, Bodapati A, Hanif A, et al. Safety and Efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): a systematic review. Cureus. 2023 Nov;15(11):e48338. doi: 10.7759/cureus.48338
- Wong S-Y, Dixon R, Pazos VM, et al. Serological response to COVID-19 vaccination in IBD patients receiving biologics. medRxiv. 2021. doi: 10.1101/2021.03.17.21253848
- Atia O, Lujan R, Greenfeld S, et al. P682 Predictors of response to biologics in ulcerative colitis: a population-based study from the epi-IIRN. J Crohn’s Colitis. 2022 Jan;16(Supplement_1):i584–i585. doi: 10.1093/ecco-jcc/jjab232.803
- Valvano M, Magistroni M, Mancusi A, et al. The usefulness of serum vitamin D levels in the assessment of ibd activity and response to biologics. Nutrients. 2021;13(2). doi: 10.3390/nu13020323
- Colombo G, Caviglia GP, Ravera A, et al. NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease. Front Med. 2023;10:1116862. doi: 10.3389/fmed.2023.1116862
- Caviglia GP, Rosso C, Stalla F, et al. On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases. J Clin Med. 2020;9(3). doi: 10.3390/jcm9030800
- Zapata-Cobo P, Salvador-Martín S, Velasco M, et al. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children. Pharmacol Res. 2023 Aug;194:106859. doi: 10.1016/j.phrs.2023.106859
- Pallikkunnath James J, Schnack Nielsen B, Langholz E, et al. P029 Expression of miR-21 in mucosal biopsies give clues to anti-TNF treatment non-response in IBD children and adults. J Crohn’s Colitis. 2022 Jan;16(Supplement_1):i150–i151. doi: 10.1093/ecco-jcc/jjab232.158
- Little RD, Ward MG, Wright E, et al. Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease—understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics. J Clin Med. 2022;11(20). doi: 10.3390/jcm11206173
- Sandborn WJ. Positioning biologics and small molecules in the management of moderate to severe IBD. Gastroenterol Hepatol (N Y). 2021 Jan;17(1 Suppl 2):8–9.
- Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD – the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013 Nov;38(10):1188–1197. doi: 10.1111/apt.12507
- Nguyen NH, Picetti D, Dulai PS, et al. Machine learning-based prediction models for diagnosis and prognosis in inflammatory bowel diseases: a systematic review. J Crohn’s Colitis. 2022 Mar;16(3):398–413. doi: 10.1093/ecco-jcc/jjab155
- Chen L, Zhang C, Niu R, et al. P915 multi-omics biomarkers for the prediction of response to biologics in patients with inflammatory bowel disease. J Crohn’s Colitis. 2024 Jan;18(Supplement_1):i1670–i1671. doi: 10.1093/ecco-jcc/jjad212.1045
- Iacucci M, Jeffery L, Acharjee A, et al. Computer-aided imaging analysis of probe-based confocal laser endomicroscopy with molecular labeling and gene expression identifies markers of response to biological therapy in IBD patients: the endo-omics study. Inflamm Bowel Dis. 2023 Sep;29(9):1409–1420. doi: 10.1093/ibd/izac233
- Ananthakrishnan AN, Luo C, Yajnik V, et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe. 2017 May;21(5):603–610.e3. doi: 10.1016/j.chom.2017.04.010